Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations.A. Inoue, Kenichi Kobayashi, Makoto Maemondo et al.|Journal of Clinical Oncology|2011Cited by 37
A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G).Nobuyuki Yamamoto, Maryam Shahidi, Isamu Okamoto et al.|Journal of Clinical Oncology|2011Cited by 25
First-line gefitinib therapy for elder advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: Multicenter phase II trial (NEJ 003 study).Yuji Minegishi, Akihiko Gemma, Makoto Maemondo et al.|Journal of Clinical Oncology|2010Cited by 20
9LBA A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 studyA. Inoue, T. Nukiwa, Kenichi Kobayashi et al.|European Journal of Cancer Supplements|2009Cited by 15
Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)Masahiro Seike, T. Nukiwa, A. Inoue et al.|Annals of Oncology|2018Cited by 10